Drugs / D744
last change Nov 2025 re-read 2 minutes ago

D744

Investigated by
Chong Kun Dang Pharmaceutical

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07304700 Oct → Nov 2025 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT05816759 May → Jun 2023 type 2 diabetes mellitus Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04906785 Jun → Jul 2021 cardiovascular disorder Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT04906798 Jun → Jul 2021 cardiovascular disorder Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT04678388 Oct → Dec 2020 cardiovascular disorder Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT04651881 Oct → Dec 2020 cardiovascular disorder Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 1 NCT04083846 Sep → Oct 2019 cardiovascular disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 1 NCT04083872 Sep → Oct 2019 cardiovascular disorder Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as D744 “Reference drug: D744 Test drug: CKD-385 64 mg formulation I Pharmacokinetic blood samples are collected up to 48 hrs.” NCT04083872
7

“Reference drug: D744, Test drug 1: CKD-385 64 mg formulation I, Test drug 2: CKD-385 64 mg formulation II.” NCT04083846

D744NCT04651881

D744NCT04678388

NCT07304700

NCT05816759

NCT04906798

NCT04906785

Route Oral “D744 Cap. 1 Cap., single oral administration under fed condition” NCT04083846